Steroid refractory graft-versus-host disease (GvHD) is associated with an absence of further therapeutic options, representing an unmet clinical need. Fecal microbiota transfer (FMT) proved to be a promising treatment modality in this challenging clinical situation. Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the study of MaaT013, a standardized, pooled-donor, high-richness microbiota biotherapeutic, in patients with steroid-dependent or steroid-refractory intestinal acute GvHD. Results were quite impressive, MaaT013 provided a safe and successful treatment, supporting further exploration of this approach. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.